For a radiologist, the difference between a 2D ultrasound slice and a full 3D volumetric image can be the difference between a guess and a diagnosis. Yet for many clinics, the capital cost of a dedicated 3D ultrasound system is prohibitive. PIUR Imaging, an Austrian medtech founded in 2015, is making a pragmatic bet that the path to better imaging runs through the machines already sitting in hospitals. Its software, cleared by the FDA and integrated with GE HealthCare LOGIQ systems, aims to upgrade existing scanners with AI-powered tomographic 3D capabilities, turning a routine probe into a tool for volumetric analysis [PIUR IMAGING, retrieved 2024].
A Wedge Into the Installed Base
The company's core proposition is a vendor-agnostic software layer. Its flagship product, PIUR tUS Infinity, is a standalone application that works with third-party ultrasound devices, while PIUR tUS inside is embedded directly into select GE HealthCare LOGIQ systems [PIUR IMAGING, retrieved 2024]. The approach sidesteps the multi-million-dollar price tag of a new 3D-capable scanner. Instead, it offers a software upgrade path, a model that lowers the barrier for adoption in cost-conscious healthcare settings. The technology uses proprietary sensor technology and AI to reconstruct 3D volumes from standard 2D sweeps, promising standardized, reproducible examinations that can cut workflow time for procedures like thyroid scans by up to 60 percent [PIUR IMAGING, retrieved 2024].
The Regulatory and Partnership Footprint
Clinical adoption in medical imaging is a story of regulatory stamps and strategic alliances. PIUR has secured both. The FDA's 510(k) clearance for PIUR tUS inside, announced in 2024, was a critical milestone, validating the software as a medical device for the U.S. market [Diagnostic Imaging, retrieved 2026]. Perhaps more telling for its commercial strategy is the partnership with GE HealthCare, one of the 'big three' in medical imaging. Having its software embedded within a major OEM's workflow is a significant distribution advantage, placing PIUR's tools directly in front of clinicians using those systems. The company has also inked a partnership with radiopharmaceutical firm Curium to advance thyroid diagnostics in Germany, indicating a focus on building application-specific pathways [Curium Pharma, 2023-10-25].
Funding and the Path to Scale
To fuel its U.S. and European expansion, PIUR closed a €5.6 million (approximately $5.99 million) growth capital round in mid-2025, led by Aescuvest Capital Partners [Healthcare IT Today, 2025-07-30]. This followed a €4.9 million Series A in 2023 led by Ascend Capital Partners [The SaaS News, July 2023]. The relatively modest funding totals, just under $6 million in disclosed capital, suggest a capital-efficient build. The company appears to be targeting specific, high-value clinical applications as beachheads, rather than a broad, undifferentiated platform launch.
| Product | Description | Key Differentiator |
|---|---|---|
| PIUR tUS Infinity | Standalone AI software for tomographic 3D imaging | Vendor-agnostic; upgrades any third-party ultrasound system [PIUR IMAGING, retrieved 2024] |
| PIUR tUS inside | Integrated software solution | FDA-cleared and embedded within select GE HealthCare LOGIQ systems [PIUR IMAGING, retrieved 2024] |
| PIUR tUS Infinity 4 for Thyroid | Application-specific module | Combines 3D imaging with AI-based automation to standardize thyroid exams [PIUR IMAGING, retrieved 2024] |
The Competitive Landscape and Execution Risks
The field of ultrasound enhancement is crowded, but PIUR's retrofit angle sets it apart from both the giants and the startups. Its competition falls into distinct camps.
- The Imaging Titans. Companies like GE HealthCare, Siemens Healthineers, and Philips sell integrated 3D/4D ultrasound as a premium feature on their high-end systems. PIUR's software does not compete with these hardware sales; it potentially complements them by adding functionality to older models, or it competes for budget allocated for premium software upgrades.
- The Handheld Disruptors. Startups like Butterfly Network and Clarius Mobile Health are democratizing access with lower-cost, portable hardware. PIUR's bet is the opposite: it assumes hospitals will keep their existing, often superior, cart-based systems and seek to enhance them.
- The Software Specialists. Competitors like TomTec Imaging Systems also provide advanced ultrasound analysis software. PIUR's differentiation rests on its specific focus on tomographic 3D reconstruction and its embedded partnership with a major OEM.
The primary risk for PIUR is one of commercial execution in a slow-moving, relationship-driven market. Selling into hospital radiology departments requires navigating lengthy procurement cycles and proving not just technical efficacy, but also workflow integration and return on investment. The partnership with GE is a powerful validator, but scaling beyond that single OEM relationship will be the next test.
The Patient at the Center
For all the talk of AI and 3D volumes, the ultimate endpoint is patient care. PIUR's initial focus areas, thyroid and carotid imaging, address conditions where precise volumetric measurement directly impacts management. In thyroid cancer, for instance, accurate 3D sizing of nodules is critical for determining whether to monitor or biopsy. The standard of care today often relies on 2D ultrasound measurements, which can be operator-dependent and less reproducible. Clinicians manually trace nodules on a single 2D slice, an imperfect proxy for a three-dimensional mass. PIUR's proposition is to replace that estimation with an automated, AI-assisted 3D volumetric calculation, aiming for a more consistent, quantitative baseline for tracking disease progression over time.
The next twelve months will be about proving that promise translates into clinical routine. The capital from its 2025 round is earmarked for scaling in the U.S. and Europe [PIUR IMAGING, retrieved 2024]. Key milestones will be broader commercial deployment of its FDA-cleared product and potentially securing additional OEM partnerships. For a company betting it can teach old ultrasound machines new tricks, the real exam is just beginning.
Sources
- [PIUR IMAGING, retrieved 2024] AI Software Solution For Your Ultrasound | https://piurimaging.com/
- [PIUR IMAGING, retrieved 2024] PIUR IMAGING Receives FDA Clearance for Revolutionary 3D Ultrasound Technology | https://www.piurimaging.com/post/piur-imaging-receives-fda-clearance-for-revolutionary-3d-ultrasound-technology-piur-tus-infinity-n
- [PIUR IMAGING, retrieved 2024] PIUR IMAGING Secures €5.6 Million Growth Capital | https://piurimaging.com/piur-imaging-secures-e5-6-million-growth-capital-to-scale-tomographic-3d-ultrasound-in-the-usa-and-europe/
- [PIUR IMAGING, retrieved 2024] PIUR IMAGING Launches PIUR tUS Infinity 4 for Thyroid | https://www.piurimaging.com/post/piur-imaging-lunches-piur-tus-infinity-4-for-thyroid-a-new-benchmark-in-tomographic-3d-ultrasound
- [The SaaS News, July 2023] Piur Imaging Raises €4.9 Million in Series A | https://www.thesaasnews.com/news/piur-imaging-raises-4-9-million-in-series-a
- [Curium Pharma, 2023-10-25] Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany | https://www.globenewswire.com/news-release/2023/10/25/2766021/0/de/CURIUM-UND-PIUR-IMAGING-K%C3%9CNDIGEN-EINE-PARTNERSCHAFT-F%C3%9CR-DIE-SCHILDDR%C3%9CSENBILDGEBUNG-IN-DEUTSCHLAND-AN-UM-TOMOGRAPHISCHE-3D-ULTRASCHALLL%C3%96SUNGEN-ZU-ERM%C3%96GLICHEN.html
- [Healthcare IT Today, 2025-07-30] PIUR IMAGING Secures €5.6 Million Growth Capital | https://www.healthcareittoday.com/2025/07/30/piur-imaging-secures-e5-6-million-growth-capital/
- [Diagnostic Imaging, retrieved 2026] PIUR tUS inside Receives 510(k) Clearance | Source snippet referenced